Obsidian Therapeutics (NASDAQ:OBX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Obsidian Therapeutics (NASDAQ:OBX) from a sell rating to a hold rating in a research note issued to investors on Sunday,Wall Street Zen reports.

A number of other equities analysts have also issued reports on OBX. Leerink Partners started coverage on Obsidian Therapeutics in a research note on Tuesday, September 22nd. They issued an “outperform” rating and a $32.00 target price for the company. TD Cowen began coverage on Obsidian Therapeutics in a research note on Thursday, August 6th. They set a “buy” rating on the stock. Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th. Lifesci Capital began coverage on Obsidian Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price objective on the stock. Finally, Piper Sandler started coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $39.00.

Obsidian Therapeutics Stock Performance

NASDAQ:OBX opened at $14.58 on Friday. Obsidian Therapeutics has a twelve month low of $12.16 and a twelve month high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.